TheraPPI raises funding

TheraPPI develops drugs that modulate protein interactions, with an oncology programme targeting ERK/MyD88 in the Ras-MAPK pathway. It has completed a second closing of its pre-seed round, of undisclosed size, with PULSALYS, FONGIT and new biotech-sector investors.

Announced on
Round
Pre-seed
Amount
Amount not disclosed
Location
Geneva
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic